Tectonic Therapeutic

Yahoo Finance • 15 days ago

Tectonic Therapeutic Surges 12% On Positive Phase 1b Topline Data For TX45

(RTTNews) - Tectonic Therapeutic, Inc. (TECX) jumped 12.33% to $20.92, gaining $2.30, after announcing positive topline results from its Phase 1b Part B clinical trial of TX45 in patients with Group 2 pulmonary hypertension associated with... Full story

Yahoo Finance • 15 days ago

Tectonic surges on phase 1b data for pulmonary hypertension asset

[Percentage Symbol with Slash Transforming into Upward Growth Graph Representing Financial Gains and Market Trends] J Studios * Tectonic Therapeutic (TECT) has skyrocketed ~29% in after-hours trading Wednesday after posting positive pha... Full story

Yahoo Finance • 16 days ago

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”)TX45 was well tolerated in patients with PH‑HFrEF with no serious... Full story

Yahoo Finance • 2 months ago

Tectonic Therapeutic a new outperform at Oppenheimer on heart drug asset

[Sign for Wall Street in New York City] Pharrel Wiliams * Oppenheimer has initiated coverage of Tectonic Therapeutic (NASDAQ:TECX [https://seekingalpha.com/symbol/TECX]) with an outperform rating citing the company's heart failure candi... Full story

Yahoo Finance • 3 months ago

Tectonic Therapeutic to Participate in September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modul... Full story

Yahoo Finance • 4 months ago

Tectonic Therapeutic Joins Russell 3000® Index

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modul... Full story

Yahoo Finance • 6 months ago

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”)In new echoca... Full story

Yahoo Finance • 8 months ago

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-H... Full story

Yahoo Finance • 9 months ago

Tectonic Announces $185 Million Private Placement

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the... Full story

Yahoo Finance • 9 months ago

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting endpoints and patient population in ongoing... Full story